| Field | Specification |
|---|---|
| Alternative names | LV-CMV-Cre-GFP-Puro | LV-CMV-Cre-GFP-PGK-Puro | CMV-Cre-GFP Lentivirus |
| Applications | |
| Purity | |
| Titer | |
| Transgene | |
| Promoter | |
| Reporter/Tag | |
| Expression regulation | |
| Selection marker | Puromycin |
| Biosafety level | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Vector Overview
Cre recombinase is a type I topoisomerase from bacteriophage P1 that catalyzes the site-specific recombination of DNA between loxP sites. Cre recombinase is used as a tool to genetically modify genes, such as to delete a segment of DNA flanked by loxP sites in cells or experimental animals. This pre-made lentivirus LV-CMV-Cre-GFP-Puro expresses Cre recombinase fusion with GFP under the CMV promoter with co-expression of puromycin resistance under the PGK promoter. Ready to use format.
Technical Details
| Catalog No. | SL100277 |
|---|---|
| Promoter | CMV |
| Transgene | Cre |
| Reporter / Tag | GFP |
| Expression Regulation | Constitutive |
| Selection Marker | Puromycin |
| Titer | >1E+9 TU/mL |
| Storage Buffer | PBS |
| Purity / Grade | In vivo grade and OK for both in vitro tissue culture infection and in vivo injection * Concentrated via PEG precipitation followed by ultra-centrifugation at 25000 rpm |
| Biosafety Level | BSL-2 |
| Sizes | 25 uL; 25 uL x 2 |
Applications
- Lentiviral Transduction: stable delivery of the cassette into dividing and non-dividing cells for long-term expression.
- Genetic Driver / Recombination: recombinase-mediated activation or excision of matching conditional alleles and DIO reporters.
Biosafety
LV-CMV-Cre-GFP-Puro is a pre-packaged lentiviral vector classified as BSL-2. Handle in a certified biosafety cabinet under institutional BSL-2 practices, decontaminate all contact surfaces and waste, and follow local regulations for viral vector work.
Safety & Handling
Store at -80°C; avoid repeated freeze-thaw cycles. Ships on dry ice. Supplied in PBS. For research use only; not for diagnostic or therapeutic use.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
Koo J, Seong CS, Parker RE, Herrera A, Dwivedi B, Arthur RA, et al. (2024) Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer. Cancer Res, 84(22), 3761-3771. 10.1158/0008-5472.CAN-23-2631
Jin R, Liu B, Liu X, Fan Y, Peng W, Huang C, et al. (2021) Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis. Mol Cancer Ther, 20(2), 274-283. 10.1158/1535-7163.MCT-20-0567
Koo J, Seong CS, Parker RE, Dwivedi B, Arthur RA, Dinasarapu AR, et al. (2023) Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer. bioRxiv. 10.1101/2023.06.14.544941